

Is Cipro still in shortage in 2026? Get the latest update on Ciprofloxacin availability, pricing, and what patients can do to fill their prescriptions.
If you or someone you care about depends on Cipro (Ciprofloxacin) to treat a bacterial infection, you may have heard about supply issues affecting this widely used antibiotic. Whether you've been turned away at the pharmacy or are just worried about availability, this article has the most current information on the Cipro shortage situation in 2026.
The short answer: it depends on the formulation.
Oral Cipro (tablets and suspension): Ciprofloxacin oral tablets are generally available in 2026. While there may be occasional localized out-of-stock situations at individual pharmacies, the drug is not currently listed on the FDA or ASHP national drug shortage lists for oral formulations. Generic Ciprofloxacin tablets are manufactured by multiple companies, which helps maintain a stable supply.
IV Cipro (injectable): The injectable form of Ciprofloxacin has had a more troubled supply history. In January 2023, Baxter discontinued its Ciprofloxacin injection product, which was a significant blow to the hospital supply chain. Remaining manufacturers like Fresenius Kabi and Hikma have worked to increase production, and the IV shortage has improved significantly, though intermittent supply tightness can still occur in hospital settings.
Several factors have contributed to Cipro availability challenges:
The antibiotic market has seen considerable consolidation over the past decade. When generic drug prices fall to very low levels (generic Ciprofloxacin can cost as little as $7 with a discount card), profit margins shrink to the point where some manufacturers exit the market. Fewer manufacturers mean less production redundancy and greater vulnerability to supply disruptions.
Like many generic medications, Ciprofloxacin relies on active pharmaceutical ingredients (APIs) that are primarily manufactured overseas, particularly in India and China. Disruptions to these global supply chains — whether from regulatory actions, geopolitical tensions, or quality issues at API facilities — can create downstream shortages.
Baxter's decision to discontinue Ciprofloxacin injection in 2023 was the single biggest disruption to Cipro supply in recent years. Hospitals that relied on Baxter had to rapidly source alternatives, creating a scramble that affected pricing and availability for months.
Cipro is prescribed for a wide range of infections — UTIs, respiratory infections, skin infections, GI infections, and more. Seasonal demand spikes (such as increased UTIs in summer months or travel-related infections) can strain local pharmacy inventories unexpectedly.
One silver lining of Cipro being available as a widely produced generic: it remains affordable.
For detailed pricing tips and coupon options, see our full guide: How to Save Money on Cipro in 2026.
While there aren't new Ciprofloxacin products specifically, patients in 2026 have more tools than ever to navigate availability issues:
If you need Cipro today, here's your action plan:
For a complete walkthrough, see: How to Find Cipro in Stock Near You (Tools + Tips).
The Cipro supply situation in 2026 is far better than it was during the peak IV shortage of 2023. Oral Ciprofloxacin tablets are widely available and affordable, and the tools to find them are better than ever. If you're having trouble at one pharmacy, don't panic — with a little effort, you can almost certainly find what you need.
Stay informed about the latest on Cipro availability by bookmarking Medfinder. And if you're a healthcare provider looking for professional resources, see our provider-focused update: Cipro Shortage: What Providers and Prescribers Need to Know in 2026.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.